Oct. 24 at 2:06 PM
Shares of Coya Therapeutics Inc fell in premarket trading Friday after the clinical-stage biotech firm priced its public offering of common stock.
The company is offering 3,636,364 shares at
$5.50 each, aiming to raise about
$20 million in gross proceeds before underwriting discounts, commissions, and expenses. Coya also granted the underwriter a 30-day option to purchase up to 545,454 additional shares at the same price.
Coya Therapeutics, which develops biologics to enhance regulatory T-cell function for neurodegenerative diseases, plans to use the net proceeds for working capital, general corporate purposes, and clinical development funding.
Lucid Capital Markets is acting as sole bookrunner, and Allele Capital Partners, through its broker-dealer Wilmington Capital Securities, is serving as financial advisor.
The offering is expected to close on or around October 27, 2025, subject to customary conditions.
$COYA